These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12728674)

  • 21. Controlling acute and chronic schizophrenia. Drug therapy today.
    Rodman MJ
    RN; 1978 Apr; 41(4):75-83. PubMed ID: 24888
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pharmacotherapy in schizophrenia--comparison of second generation antipsychotic agents].
    Melamed Y; Finkel B; Barak Y; Zipris P; Oyffe I; Weizman A; Bleich A
    Harefuah; 2005 Apr; 144(4):285-90, 301. PubMed ID: 15889614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
    Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
    Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other.
    Fleischhacker WW; Widschwendter CG
    Curr Opin Psychiatry; 2006 Mar; 19(2):128-34. PubMed ID: 16612191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects.
    Himei A; Okamura T
    Psychiatry Clin Neurosci; 2005 Oct; 59(5):556-62. PubMed ID: 16194258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
    Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
    Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The course of treatment in schizophrenia in relation to the presence of affective disturbances.
    Jaroszyński J; Rzewuska-Szatkowska M; Skowrońska J; Tarczyńska K
    Pol Med Sci Hist Bull (1973); 1975; 15(4):479-85. PubMed ID: 1223835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical classification of neuroleptics. Critical study and current prospects].
    Kapsambelis V; Gekiere C; Ginestet D
    Encephale; 1990; 16(2):63-70. PubMed ID: 1972056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Racial differences in the use of adjunctive psychotropic medications for patients with schizophrenia.
    Mallinger JB; Lamberti SJ
    J Ment Health Policy Econ; 2007 Mar; 10(1):15-22. PubMed ID: 17417044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [From neuroleptics toward antipsychotics: quality of life and schizophrenia].
    Lançon C
    Encephale; 2003 Sep; 29(Pt 2):S43-6. PubMed ID: 14710537
    [No Abstract]   [Full Text] [Related]  

  • 31. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antipsychotic agents: from phenothiazines to atypical neuroleptics of the second generation].
    Raevskiĭ KS
    Eksp Klin Farmakol; 2003; 66(2):6-9. PubMed ID: 12962040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S; Duncan GE; Marx CE; Lieberman JA
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What's atypical about atypical antipsychotic drugs?
    Meltzer HY
    Curr Opin Pharmacol; 2004 Feb; 4(1):53-7. PubMed ID: 15018839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia.
    Vohora D
    Curr Opin Investig Drugs; 2007 Jul; 8(7):531-8. PubMed ID: 17659473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Current questions on the use of neuroleptics in everyday practice].
    Perényi A; Frecska E
    Orv Hetil; 1984 Dec; 125(49):2985-8, 2991. PubMed ID: 6151164
    [No Abstract]   [Full Text] [Related]  

  • 37. [Diagnostics and therapy of depressive symptoms in schizophrenic patients].
    Bottlender R; Hampel H; Sievers M; Möller HJ
    MMW Fortschr Med; 2005 May; 147 Spec No 2():59-62. PubMed ID: 15968875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Determination of cadmium level in passive tobacco smokers schizophrenia patients].
    Kleszczewska E; Hejza J; Kleszczewski T
    Przegl Lek; 2006; 63(10):998-1001. PubMed ID: 17288201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of phenothiazine drugs on serum levels of apolipoproteins and lipoproteins in schizophrenic subjects.
    Wen F; Tan J
    Acta Pharmacol Sin; 2003 Oct; 24(10):1001-5. PubMed ID: 14531942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study.
    Molina JD; Lerma-Carrillo I; Leonor M; Pascual F; Blasco-Fontecilla H; González-Parra S; López-Muñoz F; Alamo C
    Clin Neuropharmacol; 2009; 32(1):10-5. PubMed ID: 18978498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.